All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Sarita Rani Jaiswal, Dharamshila Narayana Superspeciality Hospital, New Delhi, IN. We asked, Why can CTLA4Ig-primed sequential donor lymphocyte infusion (DLI) improve chronic GvHD and relapse-free survival (RFS) after allogeneic hematopoietic stem cell transplant (allo-HSCT)?
Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?
CTLA4Ig can block costimulation, and therefore activation, of T cells by binding to CD80 and CD86 on antigen-presenting cells. This effect is selective for T cells, as natural killer cells are resistant to CTLA4Ig-mediated anergy and in fact show an increased antitumor action. Sarita Rani Jaiswal's group has used this unique property of CTLA4Ig in the clinic to improve chronic GvHD.
Your opinion matters
8 votes - 24 days left ...
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox